纳米马达递药体系在动脉粥样硬化治疗中的应用:从化学设计到生物功能调控  

Nanomotor-based drug delivery system for atherosclerosis:from chemical design to biological function regulation

作　　者：周敏[1] 吴梓瑜 Zhou Min;Wu Ziyu(Department of Vascular Surgery,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院血管外科,南京210008

出　　处：《中华血管外科杂志》2024年第2期94-99,共6页Chinese Journal of Vascular Surgery

基　　金：国家自然科学基金(82272098)。

摘　　要：氧化应激和慢性炎症是动脉粥样硬化(AS)重要的病理基础。尽管现有的治疗策略已大大改善了心血管疾病的结局,但药物治疗带来的不良反应不可小视,并且传统治疗模式仅针对单一致病环节,难以应对AS复杂的病理过程。因此,探索新的AS递药体系具有重要意义。纳米马达是一类能够将外部环境中的能量转化为自身动能的纳米尺度机器,基于其主动运动能力和趋化行为而构建的靶向递药体系在生物医学领域展现出广阔前景。本文总结了AS的主要病理特征,阐述了其临床和新兴临床前治疗策略与挑战,并从生物医学工程的角度,介绍了应用于AS的纳米马达递药体系.Oxidative stress and chronic inflammation are important pathologic bases of atherosclerosis(AS).Although existing therapeutic strategies have greatly improved the outcomes of cardiovascular diseases,the adverse effects of drug therapy cannot be underestimated.Meanwhile,traditional treatments merely target a single pathological link within,making it difficult to cope with the complex pathological process of AS.Therefore,it is of great significance to explore new drug delivery systems for AS.Nanomotors are nanoscale machines that can convert energy from the external environment into their own kinetic energy.The targeted drug delivery system based on their active movement and chemotaxis is promising in the biomedical field.This article aims to summarize the main pathological features of AS,illustrate its clinical and emerging preclinical therapeutic strategies and challenges,and introduce the nanomotor-based drug delivery system for AS.

关 键 词：纳米马达 动脉粥样硬化 氧化应激 炎症 

分 类 号：R543.5[医药卫生—心血管疾病]